TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.250
-0.060 (-4.58%)
At close: Oct 28, 2025, 4:00 PM EDT
1.260
+0.010 (0.80%)
After-hours: Oct 28, 2025, 7:29 PM EDT
TherapeuticsMD Revenue
TherapeuticsMD had revenue of $952.00K in the quarter ending June 30, 2025, with 306.84% growth. This brings the company's revenue in the last twelve months to $2.56M, up 156.93% year-over-year. In the year 2024, TherapeuticsMD had annual revenue of $1.76M with 35.25% growth.
Revenue (ttm)
$2.56M
Revenue Growth
+156.93%
P/S Ratio
5.91
Revenue / Employee
$2,559,000
Employees
1
Market Cap
14.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.76M | 459.00K | 35.25% |
| Dec 31, 2023 | 1.30M | -68.66M | -98.14% |
| Dec 31, 2022 | 69.96M | 67.39M | 2,619.12% |
| Dec 31, 2021 | 2.57M | -62.30M | -96.03% |
| Dec 31, 2020 | 64.87M | 15.23M | 30.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TXMD News
- 2 months ago - TherapeuticsMD Announces Second Quarter 2025 Financial Results - Business Wire
- 6 months ago - TherapeuticsMD Announces First Quarter 2025 Financial Results - Business Wire
- 7 months ago - TherapeuticsMD Announces Full Year 2024 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD Announces Third Quarter 2024 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying - Benzinga
- 1 year ago - TherapeuticsMD Announces Second Quarter 2024 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD Announces First Quarter 2024 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD Announces Full Year 2023 Financial Results - Business Wire